SCHEMBL5076547

SCHEMBL5076547

CCOC1(OC)C=C(C(=O)c2ccccc2)C=CC1(OC)OC

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 3/20 0.35
HSD17B10 Q99714 1/20 0.35
ALDH1A1 P00352 5/20 0.34
LMNA P02545 4/20 0.34
HPGD P15428 3/20 0.34
RAB9A P51151 3/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
MAPK1 P28482 1/20 0.34
MAPT P10636 3/20 0.33
NPC1 O15118 2/20 0.33
TSHR P16473 1/20 0.33
POLB P06746 1/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
PTGS1 P23219 1/20 0.33
PTGS2 P35354 1/20 0.33
ATM Q13315 1/20 0.33
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2164754 0.89 ALDH1A1 (0.41) ELANEHSD17B10ALDH1A1LMNAHPGD
SCHEMBL8624753 0.80 ALDH1A1 (0.38) ELANEHSD17B10ALDH1A1LMNAHPGD
SCHEMBL27617526 0.68 ALDH1A1 (0.37) ELANEALDH1A1LMNAHPGDRAB9A
Hydrochloric Acid SCHEMBL7192938 0.67 ALDH1A1 (0.43) ALDH1A1LMNAHPGDRAB9AL3MBTL1
SCHEMBL8370734 0.66 ALDH1A1 (0.38) ELANEHSD17B10ALDH1A1LMNAHPGD
SCHEMBL210845 0.66 ALDH1A1 (0.38) ELANEHSD17B10ALDH1A1LMNAHPGD
SCHEMBL27617520 0.65 ALDH1A1 (0.41) ELANEALDH1A1HPGDRAB9AL3MBTL1
SCHEMBL27747728 0.65 ALDH1A1 (0.37) ELANEHSD17B10ALDH1A1LMNAHPGD
SCHEMBL27903354 0.65 ALDH1A1 (0.37) ELANEHSD17B10ALDH1A1LMNAHPGD
SCHEMBL3643054 0.65 ALDH1A1 (0.37) ELANEHSD17B10ALDH1A1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1361210-B1 Novel immunotherapeutic agents and their use in the reduction of cytokine levels CELGENE CORP (US) 2008-12-24 EP disclosed
US-7019030-B2 Cyano and carboxy derivatives of substituted styrenes; inhibitors of tumor necrosis factor alpha, nuclear factor kappa B, and phosphodiesterase CELGENE CORPORATION (US) 2006-03-28 US disclosed
US-20040019106-A1 Novel immunotherapeutic agents MULLER GEORGE W (US) 2004-01-29 US disclosed
EP-1361210-A2 Novel immunotherapeutic agents and their use in the reduction of cytokine levels CELGENE CORPORATION (US) 2003-11-12 EP disclosed
EP-0918746-B1 IMMUNOTHERAPEUTIC AGENTS AND THEIR USE IN THE REDUCTION OF CYTOKINE LEVELS CELGENE CORP (US) 2003-04-09 EP disclosed
US-20030045726-A1 Novel immunotherapeutic agents MULLER GEORGE W (US) 2003-03-06 US disclosed
US-6479554-B2 CYANO AND CARBOXY DERIVATIVES OF SUBSTITUTED STYRENES ARE INHIBITORS OF TUMOR NECROSIS FACTOR ALPHA , NUCLEAR FACTOR KAPPA B, AND PHOSPHODIESTERASE AND CAN BE USED TO TREAT CACHEXIA, ENDOTOXIC SHOCK, INFLAMMATORY CONDITIONS ETC. CELGENE CORPORATION 2002-11-12 US disclosed
US-20010056107-A1 Novel immunotherapeutic agents MULLER GEORGE W (US) 2001-12-27 US disclosed
US-6262101-B1 ALPHA-PYRROLIDINE, IMIDAZOLE AND THIOPHENE-SUBSTITUTED STYRENE DERIVATIVES; INHIBITORS OF TUMOR NECROSIS FACTOR ALPHA, NUCLEAR FACTOR KAPPA B, AND PHOSPHODIESTERASE CELGENE CORPORATION 2001-07-17 US disclosed
US-6130226-A Immunotherapeutic agents CELGENE CORPORATION (US) 2000-10-10 US disclosed
US-5929117-A COMPOUNDS WHICH MEDIATE ACTION OF PHOSPHODIESTERASE AND FORMATION OF TUMOR NECROSIS FACTOR AND NUCLEAR FACTORS CELGENE CORPORATION (US) 1999-07-27 US disclosed
EP-0918746-A1 IMMUNOTHERAPEUTIC AGENTS AND THEIR USE IN THE REDUCTION OF CYTOKINE LEVELS CELGENE CORPORATION (US) 1999-06-02 EP disclosed
WO-1998006692-A1 NOVEL IMMUNOTHERAPEUTIC AGENTS AND THEIR USE IN THE REDUCTION OF CYTOKINE LEVELS CELGENE CORPORATION (US) 1998-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030045726-A1 Novel immunotherapeutic agents NFKBIA, RELA, IKBKG ELANE 51/4885HSD17B10 2290/4885ALDH1A1 2212/4885
US-20040019106-A1 Novel immunotherapeutic agents NFKBIA, RELA, IKBKG ELANE 51/4885HSD17B10 2290/4885ALDH1A1 2212/4885
US-20010056107-A1 Novel immunotherapeutic agents NFKBIA, RELA, IKBKG ELANE 51/4885HSD17B10 2290/4885ALDH1A1 2212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.